IL116433A - INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS - Google Patents

INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS

Info

Publication number: IL116433A
Authority: IL; Israel
Prior art keywords: oestradiol; precursor; moiety; group; drug delivery
Prior art date: 1994-12-19

Application number

IL11643395A

Other languages

English (en)

Other versions

IL116433A0 (en

Original Assignee

Galen Chemicals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-19

Filing date

1995-12-18

Publication date

2002-02-10

1995-12-18 Application filed by Galen Chemicals Ltd filed Critical Galen Chemicals Ltd

1996-03-31 Publication of IL116433A0 publication Critical patent/IL116433A0/xx

2002-02-10 Publication of IL116433A publication Critical patent/IL116433A/en

Links

239000002243 precursor Substances 0.000 title claims abstract description 100
238000012377 drug delivery Methods 0.000 title claims abstract description 51
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title claims abstract description 23
229960005309 estradiol Drugs 0.000 title claims 3
229920000642 polymer Polymers 0.000 claims abstract description 56
239000011159 matrix material Substances 0.000 claims abstract description 38
-1 isobutyryl Chemical group 0.000 claims abstract description 27
230000000903 blocking effect Effects 0.000 claims abstract description 24
125000002252 acyl group Chemical group 0.000 claims abstract description 23
238000001727 in vivo Methods 0.000 claims abstract description 18
241000124008 Mammalia Species 0.000 claims abstract description 14
239000000126 substance Substances 0.000 claims abstract description 14
229920001296 polysiloxane Polymers 0.000 claims abstract description 11
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 10
239000012153 distilled water Substances 0.000 claims abstract description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
239000007788 liquid Substances 0.000 claims abstract description 7
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 5
125000001931 aliphatic group Chemical group 0.000 claims abstract description 5
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 4
125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims abstract description 3
125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 claims abstract description 3
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 3
125000001721 carboxyacetyl group Chemical group 0.000 claims abstract description 3
125000003897 citraconoyl group Chemical group C(\C(\C)=C/C(=O)*)(=O)* 0.000 claims abstract description 3
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 3
125000004031 fumaroyl group Chemical group C(\C=C\C(=O)*)(=O)* 0.000 claims abstract description 3
125000003099 maleoyl group Chemical group C(\C=C/C(=O)*)(=O)* 0.000 claims abstract description 3
125000003431 oxalo group Chemical group 0.000 claims abstract description 3
229920006395 saturated elastomer Polymers 0.000 claims abstract description 3
231100000252 nontoxic Toxicity 0.000 claims abstract 5
230000003000 nontoxic effect Effects 0.000 claims abstract 5
150000002762 monocarboxylic acid derivatives Chemical class 0.000 claims abstract 3
238000002657 hormone replacement therapy Methods 0.000 claims description 25
238000004519 manufacturing process Methods 0.000 claims description 20
208000024891 symptom Diseases 0.000 claims description 20
238000000034 method Methods 0.000 claims description 18
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 10
229960004400 levonorgestrel Drugs 0.000 claims description 10
239000003054 catalyst Substances 0.000 claims description 8
239000003431 cross linking reagent Substances 0.000 claims description 6
239000000583 progesterone congener Substances 0.000 claims description 6
206010033264 Ovarian hyperfunction Diseases 0.000 claims description 5
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 4
230000035558 fertility Effects 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 2
150000002009 diols Chemical class 0.000 claims 1
229940079593 drug Drugs 0.000 description 29
239000003814 drug Substances 0.000 description 29
238000013461 design Methods 0.000 description 27
238000000338 in vitro Methods 0.000 description 25
239000000262 estrogen Substances 0.000 description 23
239000000203 mixture Substances 0.000 description 17
229960000686 benzalkonium chloride Drugs 0.000 description 15
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 15
238000007429 general method Methods 0.000 description 15
239000012738 dissolution medium Substances 0.000 description 12
230000002209 hydrophobic effect Effects 0.000 description 11
229920001971 elastomer Polymers 0.000 description 10
239000000806 elastomer Substances 0.000 description 10
238000004458 analytical method Methods 0.000 description 8
235000013870 dimethyl polysiloxane Nutrition 0.000 description 8
239000004205 dimethyl polysiloxane Substances 0.000 description 8
238000003780 insertion Methods 0.000 description 8
230000037431 insertion Effects 0.000 description 8
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 8
150000003431 steroids Chemical class 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
229930182833 estradiol Natural products 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 6
238000011068 loading method Methods 0.000 description 6
230000036470 plasma concentration Effects 0.000 description 6
230000000757 progestagenic effect Effects 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
238000009792 diffusion process Methods 0.000 description 5
230000007062 hydrolysis Effects 0.000 description 5
238000006460 hydrolysis reaction Methods 0.000 description 5
230000002459 sustained effect Effects 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000007774 longterm Effects 0.000 description 4
238000002156 mixing Methods 0.000 description 4
230000016087 ovulation Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000007423 decrease Effects 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
229960003399 estrone Drugs 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
150000002763 monocarboxylic acids Chemical class 0.000 description 3
239000008188 pellet Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
239000012086 standard solution Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 3
229940070710 valerate Drugs 0.000 description 3
206010003694 Atrophy Diseases 0.000 description 2
206010027304 Menopausal symptoms Diseases 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000032683 aging Effects 0.000 description 2
230000037444 atrophy Effects 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
150000001991 dicarboxylic acids Chemical class 0.000 description 2
230000001076 estrogenic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000009245 menopause Effects 0.000 description 2
230000000955 neuroendocrine Effects 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
238000005192 partition Methods 0.000 description 2
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 2
230000028327 secretion Effects 0.000 description 2
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
230000001839 systemic circulation Effects 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
108010051152 Carboxylesterase Proteins 0.000 description 1
102000013392 Carboxylesterase Human genes 0.000 description 1
206010013786 Dry skin Diseases 0.000 description 1
208000004483 Dyspareunia Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
206010024870 Loss of libido Diseases 0.000 description 1
206010027940 Mood altered Diseases 0.000 description 1
206010048886 Onychoclasis Diseases 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
206010046477 Urethral syndrome Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960003996 chlormadinone Drugs 0.000 description 1
VUHJZBBCZGVNDZ-TTYLFXKOSA-N chlormadinone Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VUHJZBBCZGVNDZ-TTYLFXKOSA-N 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003640 drug residue Substances 0.000 description 1
230000037336 dry skin Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
230000003325 follicular Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229960005352 gestodene Drugs 0.000 description 1
SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000002706 hydrostatic effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001746 injection moulding Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
231100000863 loss of memory Toxicity 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
229960004616 medroxyprogesterone Drugs 0.000 description 1
229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
229960001786 megestrol Drugs 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000000693 micelle Substances 0.000 description 1
230000037211 monthly cycles Effects 0.000 description 1
230000007510 mood change Effects 0.000 description 1
206010029410 night sweats Diseases 0.000 description 1
230000036565 night sweats Effects 0.000 description 1
229960000417 norgestimate Drugs 0.000 description 1
KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
238000009806 oophorectomy Methods 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000011599 ovarian follicle development Effects 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000013269 sustained drug release Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
ZQZCOBSUOFHDEE-UHFFFAOYSA-N tetrapropyl silicate Chemical compound CCCO[Si](OCCC)(OCCC)OCCC ZQZCOBSUOFHDEE-UHFFFAOYSA-N 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000013271 transdermal drug delivery Methods 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
239000000003 vaginal tablet Substances 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Reproductive Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

IL11643395A 1994-12-19 1995-12-18 INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS IL116433A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IES940976		1994-12-19
IES950247		1995-04-05

Publications (2)

Publication Number	Publication Date
IL116433A0 IL116433A0 (en)	1996-03-31
IL116433A true IL116433A (en)	2002-02-10

Family

ID=26319777

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11643395A IL116433A (en)	1994-12-19	1995-12-18	INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS

Country Status (19)

Country	Link
US (1)	US5855906A (de)
EP (1)	EP0799025B1 (de)
JP (1)	JPH10510825A (de)
CN (1)	CN1138526C (de)
AR (1)	AR002010A1 (de)
AT (1)	ATE178204T1 (de)
AU (1)	AU692659B2 (de)
CA (1)	CA2207622C (de)
DE (1)	DE69508791T2 (de)
DK (1)	DK0799025T3 (de)
ES (1)	ES2133841T3 (de)
FI (1)	FI119414B (de)
GR (1)	GR3030614T3 (de)
IL (1)	IL116433A (de)
NO (1)	NO316707B1 (de)
NZ (1)	NZ298490A (de)
PE (1)	PE62796A1 (de)
TR (1)	TR199501599A2 (de)
WO (1)	WO1996019196A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6407082B1 (en) *	1996-09-13	2002-06-18	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of a vitamin D compound
US6028064A (en)	1996-09-13	2000-02-22	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of progestin products
US6511970B1 (en)	1996-09-13	2003-01-28	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en)	1996-09-13	2000-03-07	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of a Vitamin D compound
US6765002B2 (en)	2000-03-21	2004-07-20	Gustavo Rodriguez	Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6416780B1 (en)	1997-05-07	2002-07-09	Galen (Chemicals) Limited	Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
US6039968A (en) *	1997-06-24	2000-03-21	Hoechst Marion Roussel	Intravaginal drug delivery device
US20040176336A1 (en) *	2000-03-21	2004-09-09	Rodriguez Gustavo C.	Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) *	2000-03-21	2005-05-26	Rodriguez Gustavo C.	Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) *	2000-03-21	2001-11-22	Rodriguez Gustavo C.	Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US6811549B2 (en)	2001-02-16	2004-11-02	William H. Fleming	Administration of therapeutic or diagnostic agents using interlabial pad
US6962908B2 (en)	2001-12-21	2005-11-08	Warner Chilcott Company Inc.	Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
WO2003080019A1 (en) *	2002-03-27	2003-10-02	Galen (Chemicals) Limited	Intravaginal reservoir drug delivery devices
GB0222522D0 (en) *	2002-09-27	2002-11-06	Controlled Therapeutics Sct	Water-swellable polymers
DE602004026173D1 (de) *	2003-04-29	2010-05-06	Gen Hospital Corp	Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
GB0417401D0 (en)	2004-08-05	2004-09-08	Controlled Therapeutics Sct	Stabilised prostaglandin composition
EP1853272A1 (de) *	2005-02-03	2007-11-14	Duramed Pharmaceuticals, Inc.	Zusammensetzungen aus unkonjugierten östrogenen und anwendungsverfahren dafür
US20060185678A1 (en) *	2005-02-03	2006-08-24	Bronnenkant Lance J	Devices for delivering agents to a vaginal tract
JP5265359B2 (ja)	2005-08-11	2013-08-14	マサチューセッツインスティテュートオブテクノロジー	膀胱内薬物送達デバイスおよび方法
US20070077269A1 (en) *	2005-10-04	2007-04-05	Woodward John R	Method of birth control and hormone regulation
JP5137841B2 (ja) *	2005-10-13	2013-02-06	シンセスゲーエムベーハー	薬物含浸容器
GB0613333D0 (en) *	2006-07-05	2006-08-16	Controlled Therapeutics Sct	Hydrophilic polyurethane compositions
GB0613638D0 (en)	2006-07-08	2006-08-16	Controlled Therapeutics Sct	Polyurethane elastomers
AU2007274081B2 (en) *	2006-07-12	2012-08-02	Controlled Therapeutics (Scotland) Ltd.	Drug delivery polymer with hydrochloride salt of clindamycin
GB0620685D0 (en) *	2006-10-18	2006-11-29	Controlled Therapeutics Sct	Bioresorbable polymers
EP2170276B1 (de) *	2007-06-26	2018-08-22	Allergan Pharmaceuticals International Limited	Intravaginale arzneiabgabevorrichtungen zur abgabe von makromolekülen und wasserlöslichen arzneimitteln
US9586035B2 (en)	2007-12-11	2017-03-07	Massachusetts Institute Of Technology	Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
EA201170297A1 (ru)	2008-08-09	2011-08-30	Массачусетс Инститьют Оф Текнолоджи	Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
EP2437684B1 (de)	2009-06-03	2022-06-15	ForSight Vision5, Inc.	Wirkstofffreisetzung im vorderen augensegment
CN102470237A (zh)	2009-06-26	2012-05-23	塔里斯生物医药公司	用于可植入药物递送装置的固体药物片剂
US9017312B2 (en) *	2009-09-10	2015-04-28	Taris Biomedical Llc	Implantable device for controlled drug delivery
US8580294B2 (en)	2010-10-19	2013-11-12	International Partnership For Microbicides	Platinum-catalyzed intravaginal rings
US9114111B2 (en)	2011-01-10	2015-08-25	Allergan, Inc.	Methods for sustained treatment of bladder pain and irritative voiding
AU2012211960B2 (en)	2011-02-04	2016-12-01	Taris Biomedical Llc	Implantable device for controlled release of low solubility drug
JP5989780B2 (ja)	2011-09-14	2016-09-07	フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔＶｉｓｉｏｎ５，Ｉｎｃ．	眼挿入装置および方法
TWI590843B (zh)	2011-12-28	2017-07-11	信迪思有限公司	膜及其製造方法
RU2652063C2 (ru)	2012-10-26	2018-04-24	Форсайт Вижн5, Инк.	Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу
PT2968880T (pt)	2013-03-15	2025-07-07	Taris Biomedical Llc	Dispositivos de aplicação de fármaco com componente permeável a fármaco
CN105555328B (zh)	2013-06-21	2019-01-11	德普伊新特斯产品公司	膜及制造方法
CN113413393B (zh)	2013-08-19	2025-03-04	塔里斯生物医药公司	多单元药物递送装置和方法
CN104546668B (zh) *	2013-10-23	2019-03-05	国家卫生计生委科学技术研究所	液体硅橡胶为载体的药物缓控释系统的制备及应用
US10137031B2 (en)	2013-11-14	2018-11-27	International Partnership For Microbicides, Inc.	Combination therapy intravaginal rings
HUE068689T2 (hu) *	2014-04-01	2025-01-28	Poly Med Inc	Fogamzásgátló és azzal kapcsolatos eszköz
US20160296532A1 (en)	2015-04-13	2016-10-13	Forsight Vision5, Inc.	Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
KR102658706B1 (ko)	2015-04-23	2024-04-17	타리스 바이오메디컬 엘엘씨	약물-투과성 성분을 구비한 약물 전달 장치 및 방법
CN114573654B (zh) *	2020-12-01	2025-09-12	北京奇明达企业管理有限公司	17-O-乙酰-17-β雌二醇的自组装的三聚体、其制备、活性和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3545439A (en) *	1968-01-04	1970-12-08	Upjohn Co	Medicated devices and methods
US4291014A (en) *	1979-01-11	1981-09-22	Key Pharmaceuticals, Inc.	Polymeric diffusion matrix containing estradiol diacetate
US4438139A (en) *	1979-08-14	1984-03-20	Key Pharmaceuticals, Inc.	Polymeric diffusion matrix containing estrogens
SE8602666D0 (sv) *	1986-06-16	1986-06-16	Leo Ab	Intravaginal devices

1995
- 1995-12-18 IL IL11643395A patent/IL116433A/en not_active IP Right Cessation
- 1995-12-19 US US08/849,329 patent/US5855906A/en not_active Expired - Lifetime
- 1995-12-19 CA CA002207622A patent/CA2207622C/en not_active Expired - Lifetime
- 1995-12-19 NZ NZ298490A patent/NZ298490A/xx unknown
- 1995-12-19 AU AU43991/96A patent/AU692659B2/en not_active Ceased
- 1995-12-19 ES ES95942772T patent/ES2133841T3/es not_active Expired - Lifetime
- 1995-12-19 DK DK95942772T patent/DK0799025T3/da active
- 1995-12-19 TR TR95/01599A patent/TR199501599A2/xx unknown
- 1995-12-19 AR ARP950100619A patent/AR002010A1/es unknown
- 1995-12-19 JP JP8519650A patent/JPH10510825A/ja not_active Ceased
- 1995-12-19 CN CNB951968947A patent/CN1138526C/zh not_active Expired - Lifetime
- 1995-12-19 PE PE1995287516A patent/PE62796A1/es not_active Application Discontinuation
- 1995-12-19 EP EP95942772A patent/EP0799025B1/de not_active Expired - Lifetime
- 1995-12-19 AT AT95942772T patent/ATE178204T1/de not_active IP Right Cessation
- 1995-12-19 DE DE69508791T patent/DE69508791T2/de not_active Expired - Lifetime
- 1995-12-19 WO PCT/IE1995/000063 patent/WO1996019196A1/en not_active Ceased
1997
- 1997-06-17 FI FI972579A patent/FI119414B/fi not_active IP Right Cessation
- 1997-06-17 NO NO19972798A patent/NO316707B1/no unknown
1999
- 1999-06-29 GR GR990401699T patent/GR3030614T3/el unknown

Also Published As

Publication number	Publication date
NO316707B1 (no)	2004-04-13
EP0799025A1 (de)	1997-10-08
CN1138526C (zh)	2004-02-18
FI972579A0 (fi)	1997-06-17
ATE178204T1 (de)	1999-04-15
GR3030614T3 (en)	1999-10-29
WO1996019196A1 (en)	1996-06-27
CA2207622C (en)	2006-10-17
NZ298490A (en)	1999-11-29
DK0799025T3 (da)	1999-10-18
JPH10510825A (ja)	1998-10-20
IL116433A0 (en)	1996-03-31
NO972798D0 (no)	1997-06-17
CN1170353A (zh)	1998-01-14
EP0799025B1 (de)	1999-03-31
NO972798L (no)	1997-08-19
US5855906A (en)	1999-01-05
FI972579L (fi)	1997-06-17
AU4399196A (en)	1996-07-10
DE69508791D1 (de)	1999-05-06
CA2207622A1 (en)	1996-06-27
ES2133841T3 (es)	1999-09-16
FI119414B (fi)	2008-11-14
TR199501599A2 (tr)	1996-07-21
PE62796A1 (es)	1996-12-28
DE69508791T2 (de)	1999-12-02
AR002010A1 (es)	1998-01-07
AU692659B2 (en)	1998-06-11

Legal Events

Date	Code	Title
2002-06-30	FF	Patent granted
2002-12-01	KB	Patent renewed
2006-02-21	KB	Patent renewed
2016-07-31	EXP	Patent expired

Publication	Publication Date	Title
US5855906A (en)	1999-01-05	Intravaginal drug delivery devices for the administration of 17β-oestradiol precursors
US6416780B1 (en)	2002-07-09	Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
Brannon-Peppas	1993	Novel vaginal drug release applications
US8865200B2 (en)	2014-10-21	Sustained release compositions containing progesterone receptor modulators
US5543150A (en)	1996-08-06	Method of progesterone delivery and affect thereof
SK54694A3 (en)	1994-10-05	Subcutaneous implantants derivatives nomegestrol based
Nash	2019	Controlled release systems for contraception
US20080085877A1 (en)	2008-04-10	Therapeutic methods of using estrogen compositions
JPS62298532A (ja)	1987-12-25	膣挿入デバイス
US20050197651A1 (en)	2005-09-08	Vaginal ring preparation and its application
US6642219B1 (en)	2003-11-04	Progestogen-antiprogestogen regimens
IES950959A2 (en)	1996-06-26	Intravaginal drug delivery devices for the administration of 17ß-oestradiol precursors
US20230404911A1 (en)	2023-12-21	Drug delivery system for ultra-low dose estrogen combinations and methods and uses thereof
Malcolm	2008	Vaginal rings for controlled-release drug delivery
CA3259928A1 (en)	2024-02-08	DRUG DELIVERY SYSTEM FOR ULTRA-LOW DOSE ESTROGEN COMBINATIONS AND METHODS AND USES THEREOF
WO2008018872A1 (en)	2008-02-14	Therapeutic methods of using estrogen compositions
Watkinson	2001	The pharmacokinetics of drug delivery systems in hormone replacement therapy
ZA200106689B (en)	2002-11-14	Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding.
WO2010015372A1 (de)	2010-02-11	Schwangerschaftsvermeidung durch gestagene